Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

NCT04910685 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.

NCT NCT04910685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04910685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Lead sponsor
Blueprint Medicines Corporation
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 30, 2021
Completion date
September 30, 2032
Enrollment
534 (estimated)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

indolent systemic mastocytosis, smoldering systemic mastocytosis